An eight-week multicenter study to evaluate the efficacy and safety of the combination of aliskiren/ HCTZ [hydrochlorothiazide] (300/12.5 mg and 300/25 mg) in comparison with aliskiren 300 mg in patients with essential hypertension not adequately responsive to aliskiren 300 mg monotherapy
Phase of Trial: Phase III
Latest Information Update: 09 Feb 2017
At a glance
- Drugs Aliskiren; Hydrochlorothiazide
- Indications Essential hypertension
- Focus Therapeutic Use
- Sponsors Novartis
- 13 Aug 2007 Status changed from in progress to completed.
- 07 Jun 2007 Status changed from recruiting to in progress.
- 17 Dec 2006 New trial record.